Screener
NewAmsterdam Pharma Company NAMS Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | For the three months ended June 30, 2026 | For the three months ended June 30, 2025 | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|---|---|
| (In thousands of USD, except per share amounts) | ||||
| Revenue | 3,701 | 19,145 | 6,741 | 22,123 |
| Operating expenses: | ||||
| Research and development expenses | 41,673 | 27,516 | 79,682 | 72,267 |
| Selling, general and administrative expenses | 26,892 | 27,264 | 50,343 | 54,416 |
| Total operating expenses | 68,565 | 54,780 | 130,025 | 126,683 |
| Operating loss | (64,864) | (35,635) | (123,284) | (104,560) |
| Other income (expense): |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's total revenue?
- NewAmsterdam Pharma Company (NAMS) reported total revenue of $3.7M in Q2 2026.
- How has NewAmsterdam Pharma Company's total revenue changed year-over-year?
- NewAmsterdam Pharma Company's total revenue decreased by 80.7% year-over-year, from $19.15M to $3.7M.
- What is the long-term trend for NewAmsterdam Pharma Company's total revenue?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's total revenue has grown at a -39.7% compound annual growth rate (CAGR), from $102.69M to $22.5M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about NewAmsterdam Pharma Company's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude